What is LTGO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.90B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for LTGO?

P/E (TTM) is n/a and 52-week range is $13.50 to $25.93 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s LTGO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

Where is Latigo Biotherapeutics, Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in Thousand Oaks, California, US, 66.3M shares outstanding, ISIN US5179541033 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Latigo Biotherapeutics, Inc.

$LTGO

Health Care · Pharmaceuticals

Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. The company is headquartered in Thousand Oaks, California. The firm is engaged in developing non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its two product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors designed to inhibit the transmission of pain. The company is also advancing additional Nav1.8 candidates that can address alternative formulation and delivery approaches. The firm's lead product candidate, LTG-001, is an oral Nav1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain. LTG-321 is its next-generation candidate for the inhibition of Nav1.8, being developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis (OA). LTG-001 and LTG-321 are in clinical development, and LTG-418 and the Company's other product candidates and programs are in preclinical development or discovery stages.

Website

latigobio.com

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)